Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 7/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15913454 | 0.80 | FFAR1 (0.42) | GRM5FFAR1 | |
| SCHEMBL14153234 | 0.80 | FFAR1 (0.42) | GRM5FFAR1 | |
| SCHEMBL14061857 | 0.78 | FLT3 (0.45) | GRM5FLT3FFAR1KDM1A | |
| SCHEMBL14153032 | 0.78 | FLT3 (0.45) | GRM5FLT3FFAR1KDM1A | |
| SCHEMBL3392810 | 0.77 | KMT2A (0.32) | GRM5CHRM2SIGMAR1FLT3 | |
| SCHEMBL3392808 | 0.77 | KMT2A (0.32) | GRM5CHRM2SIGMAR1FLT3 | |
| SCHEMBL17395190 | 0.77 | NOS3 (0.38) | — | |
| SCHEMBL5223201 | 0.77 | NOS3 (0.38) | — | |
| SCHEMBL15913884 | 0.76 | GRM5 (0.55) | GRM5 | |
| SCHEMBL14153545 | 0.76 | GRM5 (0.55) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140221332-A1 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221332-A1 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2014-08-07 | — | — | US | disclosed |
| WO-2012162635-A1 | METABOTROPIC GLUTAMATE RECEPTORS 5 MODULATORS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2012-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221332-A1 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF | GRM5, GRIK5, GRM2 | GRM5 1/4885CHRM2 591/4885SIGMAR1 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.